121 related articles for article (PubMed ID: 7356889)
1. Plasma noradrenaline concentration in essential hypertension during long-term beta-adrenoceptor blockade with oxprenolol.
Jones DH; Daniel J; Hamilton CA; Reid JL
Br J Clin Pharmacol; 1980 Jan; 9(1):27-31. PubMed ID: 7356889
[TBL] [Abstract][Full Text] [Related]
2. Haemodynamic consequences of intrinsic sympathomimetic activity in relation to changes in plasma renin activity and noradrenaline during beta-blocker therapy for hypertension.
Man in't Veld AJ; Schalekamp MA
Postgrad Med J; 1983; 59 Suppl 3(689):140-58. PubMed ID: 6139800
[TBL] [Abstract][Full Text] [Related]
3. Increased plasma free dopamine after treatment with atenolol and oxprenolol in essential hypertension.
Kjeldsen SE; Eide I; Aakesson I; Amundsen R; Eriksen IL; Leren P
Acta Med Scand; 1983; 214(5):367-71. PubMed ID: 6660046
[TBL] [Abstract][Full Text] [Related]
4. Sympathetic reflex responses during treatment of essential hypertension with hydrallazine and oxprenolol.
Davies IB; Sever PS; Rosenthal T
Br J Clin Pharmacol; 1979 Jul; 8(1):49-51. PubMed ID: 399592
[TBL] [Abstract][Full Text] [Related]
5. Trial of combination of guanethidine and oxprenolol in hypertension.
Pearson RM; Bending MR; Bulpitt CJ; George CF; Hole DR; Williams FM; Breckenridge AM
Br Med J; 1976 Apr; 1(6015):933-6. PubMed ID: 773486
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group.
J Hypertens; 1985 Aug; 3(4):379-92. PubMed ID: 2864374
[TBL] [Abstract][Full Text] [Related]
7. Lack of beta-adrenoreceptor hypersensitivity after abrupt withdrawal of long-term therapy with oxprenolol.
Bolli P; Bühler FR; Raeder EA; Amann FW; Meier M; Rogg H; Burckhardt D
Circulation; 1981 Dec; 64(6):1130-4. PubMed ID: 6117379
[TBL] [Abstract][Full Text] [Related]
8. Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once daily.
Müller FB; Allsopp LF; Cooper GL; Bolli P; Frei P; Glaus L; Ritz R; Bühler FR
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):207S-212S. PubMed ID: 4005124
[TBL] [Abstract][Full Text] [Related]
9. Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients.
Salvetti A; Arzilli F; Pedrinelli R; Beggi P; Motolese M
Eur J Clin Pharmacol; 1982; 22(3):197-201. PubMed ID: 7049707
[TBL] [Abstract][Full Text] [Related]
10. Concentration-effect relationships for oxprenolol in patients with essential hypertension.
McInnes GT; Brodie MJ
Br J Clin Pharmacol; 1988 May; 25(5):539-45. PubMed ID: 3408634
[TBL] [Abstract][Full Text] [Related]
11. Modification of the noradrenaline related effects of smoking by beta-blockade.
Carruthers M
Psychol Med; 1976 May; 6(2):251-6. PubMed ID: 12520
[TBL] [Abstract][Full Text] [Related]
12. A comparison of single doses of bucindolol and oxprenolol in hypertensive patients.
Webster J; Petrie JC; Robb OJ; Jamieson M; Verschueren J
Br J Clin Pharmacol; 1985 Oct; 20(4):393-400. PubMed ID: 2866786
[TBL] [Abstract][Full Text] [Related]
13. The acute and chronic effect of oxprenolol and propranolol on peripheral blood flow in hypertensive patients.
Vandenburg MJ
Br J Clin Pharmacol; 1982 Nov; 14(5):733-7. PubMed ID: 7138753
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension.
McInnes GT; Brodie MJ
Eur J Clin Pharmacol; 1988; 34(6):605-11. PubMed ID: 3169112
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive and hemodynamic effects of oxprenolol versus propranolol.
Ferlinz J; Easthope JL; Hughes D; Siegel J; Tobis J; Aronow WS
Clin Pharmacol Ther; 1980 Jun; 27(6):733-43. PubMed ID: 6991196
[TBL] [Abstract][Full Text] [Related]
16. Once daily beta-blocker in hypertension--oxprenolol slow-release.
Gordon RD; Ziesak M; Rowe WS; Strakosch CR; Row G
J Int Med Res; 1981; 9(1):6-11. PubMed ID: 7009256
[TBL] [Abstract][Full Text] [Related]
17. Experience with a slow-release formulation of oxprenolol.
Waal-Manning HJ; Spears GF
N Z Med J; 1978 Apr; 87(609):245-6. PubMed ID: 275650
[TBL] [Abstract][Full Text] [Related]
18. Chronic alpha-1-adrenergic blockade increases sympathoneural but not adrenomedullary activity in patients with essential hypertension.
Jacobs MC; Lenders JW; Willemsen JJ; Thien T
J Hypertens; 1995 Dec; 13(12 Pt 2):1837-41. PubMed ID: 8903663
[TBL] [Abstract][Full Text] [Related]
19. The relative antihypertensive potency of propranolol, oxprenolol, atenolol, and metoprolol given once daily. A double-blind, crossover, placebo-controlled study in ambulatory patients.
Ravid M; Lang R; Jutrin I
Arch Intern Med; 1985 Jul; 145(7):1321-3. PubMed ID: 4015285
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with slow release oxprenolol alone, or in combination with other drugs: effects on blood pressure, lipoproteins and exercise performance.
Simons LA; England JD; Balasubramaniam S; Viles L
Aust N Z J Med; 1982 Dec; 12(6):612-6. PubMed ID: 6962709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
